HIGHLIGHTS
- who: Kangdi Xu and collaborators from the Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Qing Chun Road, Hangzhou, China have published the research work: SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis, in the Journal: Cells 2023, 12, 25. of /2023/
- what: Taken together, this study provides strong evidence that SMYD2 enhances HCC progression by regulating glutamine metabolism, may serve as a promising prognostic biomarker, and act as a potential therapeutic target in HCC.
- how: The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.